Evidence map›Paper›PMID 7541611›Full record

ArticleThe American journal of pathology1995

De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct.

A Matolcsy, A Chadburn, D M Knowles

Abstract read
In one paragraph

Article in The American journal of pathology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 103 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. U-RT1 - A new model for Richter transformation.Neoplasia (New York, N.Y.) · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Current trends in the management of Richter's syndrome.International journal of hematologic oncology · 2018
    Review
  9. Article
  10. Review
  11. Article
  12. CD5+ diffuse large B-cell lymphoma with hemophagocytosis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

A MatolcsyDepartment of Pathology, New York Hospital, Cornell Medical Center, NY 10021, USA.
A Chadburn
D M Knowles
NewYork–Presbyterian Hospital · US

Funding

NEI NIH HHS EY06337
6 · The paper itself

Abstract

Diffuse large B cell lymphomas (DLBLs) represent a heterogeneous collection of aggressive non-Hodgkin's lymphomas that can arise either de novo or as a result of transformation from chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphomas, or lymphomas of mucosa-associated lymphoid tissue. A small percentage of DLBLs express the CD5 antigen. The majority of these cases have evolved from a pre-existing low grade non-Hodgkin's lymphoma (Richter's syndrome). However, we identified and characterized nine CD5-positive DLBLs in which the patients did not have a previous history or concomitant evidence of chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma, or mucosa-associated lymphoid tissue-associated non-Hodgkin's lymphoma, suggesting that they arose de novo. All nine cases expressed CD20 and monotypic immunoglobulin, all eight cases examined expressed CD19, CD22 and CD43, eight of the nine cases expressed HLA-DR, and two of eight cases expressed CD11c. None of the cases expressed CD3, CD10, CD11b, CD21, CD23 or CD30. CD5 expression by these cells was found to be identical to that of CD5-positive B cell chronic lymphocytic leukemia by quantitative polymerase chain reaction analysis of CD5 mRNA. These nine de novo CD5-positive DLBLs exhibited clonal immunoglobulin heavy and light chain gene rearrangements but lacked integration of the Epstein-Barr virus genome and structural alterations of the bcl-1, bcl-2, c-myc, H-ras, K-ras, and N-ras proto-oncogenes and the p53 tumor suppressor gene. However, bcl-6 proto-oncogene rearrangement, which is involved in chromosome band 3q27 aberrations, was found in four cases (44.4%). This is comparable with the frequency of bcl-6 gene rearrangement in CD5-negative DLBL. In contrast, bcl-6 gene rearrangement was absent in six cases of DLBL associated with Richter's syndrome. These findings suggest that de novo CD5-positive DLBLs are genotypically similar to CD5-negative DLBLs and may be pathogenetically distinct from the DLBLs associated with Richter's syndrome.

Indexed as

AgedAged, 80 and overAntigens, CDBase SequenceCD5 AntigensDNA-Binding ProteinsDNA, NeoplasmDNA PrimersFemaleGenes, Tumor SuppressorGenotypeHerpesvirus 4, HumanHumansImmunophenotypingLeukemia, Lymphocytic, Chronic, B-CellLymphoma, B-CellAntigens, CDCD5 AntigensDNA-Binding ProteinsDNA, NeoplasmDNA PrimersMAS1 protein, humanOligonucleotide ProbesProto-Oncogene MasProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-6Transcription Factors

Identifiers

PMID7541611
PMCPMC1869880
OpenAlexW103163113

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.